Compare Broadcom Inc (AVGO) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs ClearPoint Neuro Inc — how do they compare? Broadcom Inc trades at $414.98 (market cap $1.98T), while ClearPoint Neuro Inc trades at $15.3 (market cap $454.21M). The key difference: Broadcom Inc is far larger — about 4359.2× ClearPoint Neuro Inc's market cap, and Broadcom Inc pays a 0.62% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AVGO | CLPT | |
|---|---|---|
Market Cap | $1.98T | $454.21M |
Sector | Technology | Health |
52-Week High | $481.57 | $29.60 |
52-Week Low | $289.60 | $8.66 |
Enterprise Value | $2.02T | $488.79M |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $419.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong support at $412. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 estimate. Revenue grew to $63.89 billion in 2025, and net income surged to $23.13 billion, reflecting a 36.19% margin. Analysts maintain a strong buy consensus, with a $510.21 price target, citing AI-driven growth prospects.
The outlook for AVGO remains positive, driven by AI semiconductor demand and solid cash flow generation. However, high valuation multiples like a P/E of 69.23 pose risks if growth slows. Competitive pressures in the chip industry and macroeconomic volatility could challenge future performance, but institutional confidence and consistent earnings strength support a favorable investment case for long-term holders.
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
